Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, crossover study to assess the safety,
tolerability, and pharmacokinetics of single doses of AUT00201 at 100 mg or matching placebo
in patients with myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK).